Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
